CBL-514 Endpoints: Primary, Secondary and Exploratory
Identify the question chosen in advance
The 2026 CBL-514 paper names a clinician-rated primary outcome and additional participant-rating and MRI outcomes.[1] Those measures describe different aspects of the study. A favorable result on one should not be relabeled as success on another.
FDA’s multiple-endpoints guidance explains why numerous comparisons can increase false-positive conclusions unless the analysis addresses multiplicity.[2] The useful question is not simply how many outcomes improved, but which claims the planned statistical testing can support.
Why choosing the best result afterward changes the question
Original illustration: imagine a research report containing ten outcome measurements at four visits. Highlighting whichever of the 40 comparisons looks strongest is a different exercise from evaluating one endpoint selected before the data were examined.
The selected finding may still be scientifically interesting. Its role is to generate a question for further work unless a valid testing plan gives it confirmatory support. Our suggested summary therefore labels each result as primary, secondary or exploratory using the source’s terminology.
A subgroup adds another layer. A result among participants with a particular baseline feature is not automatically the overall trial result. Record the subgroup definition, size and whether it was planned. A headline should not promote the subgroup conclusion beyond the evidence supplied.
Build a claim-to-endpoint map
For every sentence about CBL-514 performance, write the matching outcome name, visit, population and statistical status. This makes it easier to catch accidental substitutions: appearance for volume, regional measurements for total-body change, or exploratory analysis for the primary endpoint.
- Primary: what decided the study’s main efficacy question?
- Secondary: what additional questions were tested, and in what order?
- Exploratory: what findings need confirmation?
- Unreported: which planned measurements cannot be evaluated from the available document?
A strong review can describe promising exploratory work without presenting it as settled. It also avoids implying that a published clinical finding verifies the properties of a retail research vial.
Frequently asked questions
Are secondary endpoints unimportant?
No. They may provide valuable additional evidence, but their interpretation depends on the design, prespecification and testing plan.
Does a positive subgroup result prove the overall trial succeeded?
No. A subgroup analysis and the trial's primary analysis answer different questions.
Continue your CBL-514 research
Compare the original study evidence with the documentation for the specific material you are reviewing.
